Commentary: British biotech industry lagging

09/14/2004 | Guardian (London), The

Heather Tomlinson of The Guardian writes that her country's slow growth in the biotechnology sector is partly the result of U.S. firms reaping most of the financial gains from highly effective drugs for rheumatoid arthritis, such as Remicade, Enbrel and Humira, all developed by British scientists. She says the U.K. biotechnology industry lags behind because, unlike its American counterparts, it fails to make its research findings commercially viable, and many companies are unwilling to take the financial risk necessary to bring new therapies to the market.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT